



RESTORE MOMENTUM

17th February 2020

Mercure Hotel MOA - Stephanstraße 41, 10559 Berlin - Germany



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 820292.



Health by Advanced Therapies

Monday, 17th February 2020

09.30-10.00 Registration for all Participants

Welcome

Plenary Room

10.00-10.45 **Welcome, the objectives of the Momentum meeting**
Hans-Dieter Volk - Charité Universitätsmedizin Berlin, Germany

10.45-11.15 *Coffee break*

Session I - Involvement of Patient Organisations in ATMP Development: The view from a Patient Organisation/Advocate Perspective

11.15-11.35 **People with rare diseases and access to new treatments**
Karolina Hanslik - EURORDIS, Belgium

11.35-11.55 **A patient advocate's perspective on cancer and why we need a cancer mission**
Bettina Ryll - Melanoma Patient Network Europe (MPNE) Sweden and Mission Board for Cancer, Sweden

11.55-12.15 **The added value of the patients voice**
Sabine Dupont - International Diabetes Federation-Europe (IDF Europe), Belgium

Session II - Regulatory aspects related to CRISPR and cross border healthcare for CAR-T cell therapy

12.15-13.00 **Off-targets assessment of CRISPR/Cas9 products**
Toni Cathomen - Universitätsklinikum Freiburg, Germany

13.00-13.30 **Setting up a cross-border institute for CAR-T cell therapy**
Johan Van Eldere - Katholieke Universiteit Leuven, Belgium

13.30-14.30 *Lunch*

Session III - Regulatory challenges facing iPSC, AAV-based gene therapy and CAR T manufacturing technology transfer

- 14.30-15.00 **Induced Pluripotent Stem Cells: maximising the impact of RESTORE research through standards use, quality testing, and awareness of regulatory requirements.**
Stephen Sullivan - Global Alliance for iPSC Therapies, UK
- 15.00-15.30 **Transfer of CAR T manufacturing technologies**
Ulrike Köhl - Fraunhofer-Institut für Zelltherapie und Immunologie, Germany
- 15.30-16.00 **Regulatory challenges currently facing AAV based therapies**
Hildegard Büning - Universitätsmedizin Neumarkt am Mieresch Campus Hamburg, Germany
- 16.00-16.30 *Coffee break*

Session IV - The public view of ATMPs

- 16.30-16.45 **Survey - Perception of Advanced Therapies in the EU**
Gady Goldsobel - Charité Universitätsmedizin Berlin, Germany
- 16.45-17.00 **Survey - The view of professionals on ethical, regulatory and technological obstacles for translation of ATMPs**
Michael Apel - Miltenyi Biotec GmbH, Germany
- 17.00-17.30 **Closing remarks and farewell**
Hans-Dieter Volk - Charité Universitätsmedizin Berlin, Germany